Frank Gentile, Ph.D.
Chief Operating Officer
Frank Gentile joined Third Rock Ventures in 2015 to focus on research and development opportunities throughout the portfolio. He brings nearly 25 years of experience working with pharmaceutical and biotechnology companies, including spending 12 years with Tekla Capital Management LLC, formerly Hambrecht & Quist Capital Management LLC, where he most recently served as senior vice president. In this role, Frank oversaw and executed biotechnology and health care investments in public and private companies in the areas of oncology, cardiovascular, infectious diseases, rare diseases, medical devices and diagnostics and discovery tools and served as a member of the board of directors in several private companies.
Prior to Tekla, Frank oversaw technology research and development programs while serving as vice president, technology program management at Millennium Pharmaceuticals and earlier in his role as vice president, product development at Curis. Before that, Frank served as vice president, program management at Reprogenesis, Inc., where he was responsible for all program management, partnership and intellectual property functions. Earlier in his career, Frank held roles of increasing responsibility at CytoTherapeutics, Inc. He served as an adjunct associate professor of pharmacology and biotechnology in the division of biology and medicine at Brown University.
Frank competed his post-doctoral work at the Swiss Federal Institute of Technology in Zurich and received his Ph.D. in chemical engineering from the Massachusetts Institute of Technology, where he was a G.E. Fellow. Additionally, Frank holds a B.E. in chemical engineering from The Cooper Union for the Advancement of Science and Art. He is a certified 4th degree black belt instructor in Tae Kwon Do.
Why Casma, Why Me?
Casma has strong potential to bring a new therapeutic mechanism to patients with unmet medical needs, and in turn, to dramatically impact a wide range of illnesses, and I am excited to help drive these efforts forward. Being part of a team that can realize such broad potential and hope for patients is why I am here.